Experienced in Teratoma of the Mediastinum

Dr. Russell Z. Szmulewitz

Hematology Oncology | Hematology | Oncology
The University Of Chicago
1101 S Canal St, Suite 201, 
Chicago, IL 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Offers Telehealth
Experienced in Teratoma of the Mediastinum
The University Of Chicago
1101 S Canal St, Suite 201, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Russell Szmulewitz is a Hematologist Oncology specialist and a Hematologist in Chicago, Illinois. Dr. Szmulewitz is rated as an Experienced provider by MediFind in the treatment of Teratoma of the Mediastinum. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Renal Cell Carcinoma (RCC), Prostatectomy, and Orchiectomy. Dr. Szmulewitz is currently accepting new patients.

His clinical research consists of co-authoring 85 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in IL
Hospital Affiliations
The University Of Chicago Medical Center
Northshore University Healthsystem - Evanston Hospital
Uchicago Medicine Northwest Indiana
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

THE UNIVERSITY OF CHICAGO
1101 S Canal St, Suite 201, Chicago, IL 60607
Other Locations
THE UNIVERSITY OF CHICAGO MEDICAL CENTER
5841 S Maryland Ave, Chicago, IL 60637

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
Enrollment Status: Recruiting
Publish Date: September 11, 2025
Intervention Type: Procedure, Drug, Other, Radiation
Study Drugs: Abiraterone, Bicalutamide, Degarelix, Docetaxel, Flutamide, Goserelin acetate, Histrelin acetate, Leuprolide acetate, Nilutamide, Prednisone, Triptorelin
Study Phase: Phase 3
Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Salvage Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) *INtensifying Treatment for NOde Positive Prostate Cancer by VArying the Hormonal ThErapy
Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Salvage Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) *INtensifying Treatment for NOde Positive Prostate Cancer by VArying the Hormonal ThErapy
Enrollment Status: Recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Abiraterone acetate, Apalutamide, Hormone therapy, Prednisone
Study Phase: Phase 3
A Phase I Trial of Enzalutamide Plus the Glucocorticoid Receptor Antagonist CORT-125134 (Relacorilant) for Patients With Metastatic Castration Resistant Prostate Cancer (CRPC)
A Phase I Trial of Enzalutamide Plus the Glucocorticoid Receptor Antagonist CORT-125134 (Relacorilant) for Patients With Metastatic Castration Resistant Prostate Cancer (CRPC)
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Drug
Study Drugs: Enzalutamide, Relacorilant
Study Phase: Phase 1
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Enrollment Status: Active_not_recruiting
Publish Date: September 23, 2025
Intervention Type: Drug
Study Drugs: 177Lu-PSMA-617, Androgen Receptor Directed Therapy, Androgen Deprivation Therapy
Study Phase: Phase 3
A Phase III Double Blinded Study of Early Intervention After RADICAl ProstaTEctomy With Androgen Deprivation Therapy With or Without Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)
A Phase III Double Blinded Study of Early Intervention After RADICAl ProstaTEctomy With Androgen Deprivation Therapy With or Without Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Drug
Study Drugs: Darolutamide, Goserelin acetate, Leuprolide acetate, Triptorelin
Study Phase: Phase 3
BRCAAway: A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
BRCAAway: A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
Enrollment Status: Active_not_recruiting
Publish Date: August 30, 2023
Intervention Type: Drug
Study Drugs: Olaparib, Abiraterone acetate, Prednisone
Study Phase: Phase 2
A Randomized Double-Blind, Placebo-Controlled Study Of The Effects Of MPX Capsules On Rising Prostate-Specific Antigen Levels In Alanine/Alanine SOD2 Genotype Men Following Initial Therapy For Prostate Cancer
A Randomized Double-Blind, Placebo-Controlled Study Of The Effects Of MPX Capsules On Rising Prostate-Specific Antigen Levels In Alanine/Alanine SOD2 Genotype Men Following Initial Therapy For Prostate Cancer
Enrollment Status: Terminated
Publish Date: May 22, 2023
Intervention Type: Drug
Study Drug: Muscadine Plus
Study Phase: Phase 3
A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors
Enrollment Status: Terminated
Publish Date: July 15, 2022
Intervention Type: Drug, Biological
Study Drugs: IL-2, Fludarabine, Cyclophosphamide
Study Phase: Phase 1
A Phase I/II Trial of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Mifepristone for Patients With Metastatic Castration Resistant Prostate Cancer (CRPC)
A Phase I/II Trial of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Mifepristone for Patients With Metastatic Castration Resistant Prostate Cancer (CRPC)
Enrollment Status: Completed
Publish Date: July 13, 2022
Intervention Type: Drug, Other
Study Drugs: Enzalutamide, Mifepristone
Study Phase: Phase 1/Phase 2
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Enrollment Status: Completed
Publish Date: February 08, 2022
Intervention Type: Biological
Study Phase: Phase 1
A Phase II Randomized Prospective Trial of Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer (CRPC) Patients Progressing on Enzalutamide
A Phase II Randomized Prospective Trial of Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer (CRPC) Patients Progressing on Enzalutamide
Enrollment Status: Terminated
Publish Date: April 09, 2021
Intervention Type: Drug
Study Phase: Phase 2
Phase 2 Study of Recombinant Glycosylated Human Interleukin-7 (CYT107) After Completion of Standard Therapy With Sipuleucel-T (Provenge®) in Pts w/ Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer(mCRPC)
Phase 2 Study of Recombinant Glycosylated Human Interleukin-7 (CYT107) After Completion of Standard Therapy With Sipuleucel-T (Provenge®) in Pts w/ Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer(mCRPC)
Enrollment Status: Completed
Publish Date: July 09, 2019
Intervention Type: Biological, Other
Study Phase: Phase 2
View 11 Less Clinical Trials

85 Total Publications

SOX2 utilizes FOXA1 as a heteromeric transcriptional partner to drive proliferation in therapy-resistant prostate cancer.
SOX2 utilizes FOXA1 as a heteromeric transcriptional partner to drive proliferation in therapy-resistant prostate cancer.
Journal: bioRxiv : the preprint server for biology
Published: August 12, 2025
Similar Doctors
Distinguished in Teratoma of the Mediastinum
Dr. Amaryllis Gil
Hematology Oncology | Palliative Medicine | Hematology
Distinguished in Teratoma of the Mediastinum
Dr. Amaryllis Gil
Hematology Oncology | Palliative Medicine | Hematology

Endeavor Health Medical Group

177 E Brush Hill Rd, 
Elmhurst, IL 
 (15.4 miles away)
630-646-6020
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Amaryllis Gil is a Hematologist Oncology specialist and a Palliative Medicine provider in Elmhurst, Illinois. Dr. Gil is rated as a Distinguished provider by MediFind in the treatment of Teratoma of the Mediastinum. Her top areas of expertise are Testicular Cancer, Teratoma of the Mediastinum, Paget Disease of the Breast, and Breast Cancer. Dr. Gil is currently accepting new patients.

Distinguished in Teratoma of the Mediastinum
Dr. Ariel Polish
Oncology | Hematology Oncology
Distinguished in Teratoma of the Mediastinum
Dr. Ariel Polish
Oncology | Hematology Oncology

Endeavor Health Medical Group

2650 Ridge Ave, Suite 2218a, 
Evanston, IL 
 (13.9 miles away)
847-503-4222
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ariel Polish is an Oncologist and a Hematologist Oncology provider in Evanston, Illinois. Dr. Polish is rated as a Distinguished provider by MediFind in the treatment of Teratoma of the Mediastinum. His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Lung Cancer, and Pleuropulmonary Blastoma. Dr. Polish is currently accepting new patients.

Randy S. Rich
Advanced in Teratoma of the Mediastinum
Dr. Randy S. Rich
Hematology | Oncology
Advanced in Teratoma of the Mediastinum
Dr. Randy S. Rich
Hematology | Oncology

Illinois Cancer Specialists

880 W Central Rd, 
Arlington Heights, IL 
 (22.9 miles away)
847-259-4482
Languages Spoken:
English
See accepted insurances

Randy Rich is a Hematologist and an Oncologist in Arlington Heights, Illinois. Dr. Rich is rated as a Distinguished provider by MediFind in the treatment of Teratoma of the Mediastinum. His top areas of expertise are Familial Pancreatic Cancer, Lung Cancer, Pleuropulmonary Blastoma, Pancreatic Cancer, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Szmulewitz's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 30 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile